| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
137,271,000 |
| Market
Cap: |
4.54(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,197,775 |
| 52
Week Range: |
$29.84 - $60.16 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1083 |
| Guru Rank Value : 0 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
96,277 |
267,505 |
472,458 |
934,416 |
| Total Sell Value |
$3,489,490 |
$11,031,343 |
$22,247,906 |
$47,925,801 |
| Total People Sold |
8 |
8 |
9 |
10 |
| Total Sell Transactions |
20 |
40 |
73 |
114 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-06-17 |
4 |
S |
$32.91 |
$65,820 |
D/D |
(2,000) |
140,610 |
|
-2% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-06-17 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,610 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-06-16 |
4 |
S |
$33.80 |
$169,000 |
D/D |
(5,000) |
403,108 |
|
2% |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-06-05 |
4 |
S |
$32.04 |
$277,434 |
D/D |
(8,659) |
52,028 |
|
-3% |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-06-05 |
4 |
S |
$32.10 |
$116,716 |
D/D |
(3,636) |
29,658 |
|
-3% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-06-03 |
4 |
S |
$31.88 |
$63,760 |
D/D |
(2,000) |
140,610 |
|
-4% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-06-03 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,610 |
|
- |
|
| Lee Sung |
EVP, Chief Financial Officer |
• • – |
2025-06-02 |
4 |
D |
$31.21 |
$154,958 |
D/D |
(4,965) |
69,477 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-06-02 |
4 |
S |
$31.22 |
$156,100 |
D/D |
(5,000) |
408,108 |
|
-6% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-05-20 |
4 |
S |
$31.98 |
$63,960 |
D/D |
(2,000) |
140,255 |
|
-2% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-05-20 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,255 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-05-16 |
4 |
S |
$30.93 |
$154,650 |
D/D |
(5,000) |
412,629 |
|
-7% |
|
| Bhanji Muna |
Director |
• • – |
2025-05-15 |
4 |
S |
$29.73 |
$43,227 |
D/D |
(1,454) |
23,510 |
|
-11% |
|
| Harrington Robert Arthur |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
22,315 |
|
- |
|
| Henderson John T |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
73,681 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
32,181 |
|
- |
|
| Bhanji Muna |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
24,964 |
|
- |
|
| Landry Robert E |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
7,333 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
30,610 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
33,294 |
|
- |
|
| Parshall B Lynne |
Director |
• • – |
2025-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,333 |
27,933 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-05-06 |
4 |
S |
$35.01 |
$70,020 |
D/D |
(2,000) |
140,255 |
|
2% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-05-06 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,255 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-05-05 |
4 |
S |
$36.68 |
$146,793 |
D/D |
(4,002) |
60,687 |
|
10% |
|
| Blum Robert I |
President & CEO |
• • – |
2025-04-29 |
4 |
S |
$40.96 |
$204,800 |
D/D |
(5,000) |
417,629 |
|
20% |
|
891 Records found
|
|
Page 1 of 36 |
|
|
0.12 (0.36%) 
